DailyIQ
Last updated1 minute ago

BIIB·Biogen Inc.

$224.52
+1.63 (+0.73%)
High
$228.00
Open
$222.93
Market Cap
32.32B
52W High
$230.49
Low
$222.93
P. Close
$224.52
P/E
38.72
52W Low
$138.00
Fwd P/E
13.48
DailyIQ Est.
$247.83
Inst. Ownership
55.1%
Short Interest
4.03%
Days to Cover
7.6
Technical Score (1D)
86
BULLISH
News Sentiment
63
BULLISH
On Oct 6, analysts projected that Biogen Inc. would report a modest earnings per share beat in its third‑quarter results, with expectations of $2.14 versus a consensus of $2.07, and revenue projected to remain flat at about $2.6 billion. The forecast was based on lower cost of goods sold and research and development expenses that were expected to offset the impact of upcoming lupus trial data. On the same day, another analysis highlighted Biogen’s consistent track record of beating earnings estimates, noting that the company’s most recent quarter earnings of $3.60 per share had surpassed the $3.04 consensus by 18.42 percent. The report also pointed out that the company’s earnings guidance had been trending upward, suggesting a continued likelihood of future beats. Both sources emphasized that Biogen’s financial outlook remained largely unchanged, with no significant shift in strategic direction.
LOW TARGET
$175 -22.1%
2 analysts
MEAN TARGET
$238 +6.1%
23 analysts
HIGH TARGET
$300 +33.6%
19 analysts
PRICE RANGE
$175.00 - $300.00
SB / B / H / S / SS
10/20/12/1/1
DAILYIQ EST.
$247.83 (+10.4%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NMS
Country
United States
Website
Symbol
BIIB
Description
Biogen Inc. is a global biotechnology company focused on discovering and delivering therapies for neurological and neurodegenerative diseases. The company's core business revolves around developing treatments for multiple sclerosis, spinal muscular atrophy, and other conditions like Friedreich's Ataxia and amyotrophic lateral sclerosis. Biogen's portfolio includes established brands such as TECFIDERA and TYSABRI, as well as biosimilars targeting rheumatoid arthritis and certain lymphomas. Furthermore, Biogen actively engages in research and development to expand its pipeline, exploring potential treatments for Alzheimer's disease, Parkinson's disease, and other neurological disorders, often through collaborations with other biopharmaceutical companies. Headquartered in Cambridge, Massachusetts, Biogen aims to address unmet medical needs within the challenging field of neuroscience.
Bought (1Y)
0 shares
$0
Sold (1Y)
1,194 shares
$242K
Godbout SeanChief Accounting Officer
Option Exercise27 shares2026-10-02
Godbout SeanChief Accounting Officer
Tax Withholding8 shares2026-10-02
Godbout SeanChief Accounting Officer
Option Exercise27 shares2026-10-02
Godbout SeanChief Accounting Officer
Award/Grant985 shares2026-10-01
Parini MichaelChief Legal Officer
Award/Grant7,405 shares2026-09-01
72/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
75.7%
Net Margin
13.1%
Revenue CAGR
6.5%
Current Ratio
2.68x
Debt / Equity
0.34x
Return on Equity
7.1%
Earnings Summary
Biogen Inc. is a global biotechnology company focused on discovering and delivering therapies for neurological and neurodegenerative diseases, operating within the drug manufacturers sector and specifically the general drug manufacturing industry. The company’s core portfolio includes established brands such as TECFIDERA and TYSABRI, with a growing emphasis on expanding into nephrology and immunology through products like EMPAVELI and Leqembi. In the most recent two quarters, Biogen reported EPS of $3.02 in Q1 2025 and $5.47 in Q2 2025, both beating analyst estimates of $2.95 and $3.88 respectively, while revenue rose from $2.43 billion to $2.65 billion, a 8.9% increase that outpaced prior quarter growth of 3.4% from Q4 2024 to Q1 2025; the company consistently beat EPS estimates in all four quarters examined, with revenue growth accelerating in Q2 2025. Historically, Biogen has maintained a YoY revenue growth trajectory of roughly 5–7% over the past three years, with EPS growth outpacing revenue in most periods, indicating efficient cost management; notable is the sustained revenue expansion despite occasional EPS misses in earlier years, underscoring a resilient top line. Recent news highlights the FDA label expansion for EMPAVELI to adolescents 12 and older, a catalyst expected to lift sales in the nephrology segment, and the launch of the subcutaneous Leqembi Pen in Japan, which could broaden the Alzheimer’s patient base and improve adherence; these developments are likely to influence next quarter’s revenue mix.

EPS

EstBeatMiss
$1.05$2.30$3.55$4.80$6.05Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.03 - -
Q2'26$2.03$3.60+77.4%
Q1'26$2.95$3.57+20.9%
Q4'25$1.63$1.99+22.4%
Q3'25$3.88$4.81+23.9%
Q2'25$3.88$5.47+41.0%

Revenue

EstBeatMiss
$2.2B$2.3B$2.5B$2.7B$2.8BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.7B - -
Q2'26$2.5B$2.7B+9.3%
Q1'26$2.2B$2.5B+10.2%
Q4'25$2.2B$2.3B+1.4%
Q3'25 - $2.5B -
Q2'25 - $2.6B -

Market Data

BIIB Stock Snapshot

BULLISH86/100
$224.52+$1.63 (0.7%)
Market cap
32.32B
P/E ratio
38.7
Day range
$222.93 – $228.00
News sentiment
63/100 · Bullish
Analyst target
$238.18 (+6.1%)
Consensus
Buy · 44 analysts
52-week range+62.7% off low · -2.6% from high
$138.00$230.49
Price $224.52 DailyIQ Est. $247.83

BIIB is trading with the trend behind it, which is what pushes the technical read bullish. In Healthcare, names this size usually take direction from sector flows before company-level news.

Reverse DCF

What growth is priced into BIIB?

CHEAP

At today's price, Biogen Inc. needs to grow free cash flow about -0.1% a year for the next 10 years to justify its valuation at a 7.70% cost of capital. Over its actual history it has compounded free cash flow at 5.1% a year, so the market is asking for 5.3 percentage points below its own delivered rate. On that basis BIIB looks priced below what its own growth record supports.

Implied FCF growth
-0.1%
Historical FCF CAGR
5.1%
Growth gap
-5.3 pts
Verdict
CHEAP
Discount rate (WACC)
7.70%
Beta
0.64

Behaviour On Record

What BIIB's own history says about today's numbers

Realized volatility (21d)
24.2% 29th pct
Below its peak
-48.5%
vs 200-day average
+14.6%
Up days (1y)
52%

Biogen Inc. is currently running 24.2% annualised volatility over the last 21 sessions. Measured against BIIB's own 13 years of daily returns rather than a market-wide average, that is the 29th percentile — on the quiet side for this stock, against a typical reading of 29.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BIIB is trading -48.5% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -31.0%, and the deepest was -46.2% in 2021. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +14.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 82nd percentile — a wider gap than this stock usually carries. Over the past year BIIB closed higher on 52% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, BIIB finished the month higher 4 of 13 times, with a median return of -2.0% and an average of -1.3%. Its strongest month historically has been November at +2.1% on average, its weakest March at -4.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BIIB has opened more than 2% away from the prior close in 108 of 3,266 sessions (3.3% of the time), with the largest gaps running +5.7% and -30.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, BIIB moved an average of 3.1% in the session after earnings, closing higher 0 of those 3 times, with a median move of -3.6% and a largest of -3.8%.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against BIIB's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BIIB's sector?

Biogen Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
64

Options Market

What is the options market pricing for BIIB?

CallsPuts

For Biogen Inc.'s nearest expiry (2026-10-09, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.84), with at-the-money implied volatility around 56.6%. The options market is pricing roughly a ±3.4% move by that expiry — a range of about $217.19–$232.53.

Put/call ratio (2026-10-09)
0.84
ATM implied volatility
56.6%
Total open interest
1,868
Expected move by 2026-10-09
±3.4% ($217.19–$232.53)

Analyst Rating Changes

Are analysts turning bullish or bearish on BIIB?

HSBC most recently reiterated its rating on Biogen Inc. to Reduce on Sep 10, 2026 with a price target of $175 (from $165). Over the last 90 days, coverage has run 2 upgrades against 0 downgrades, a net bullish lean.

Latest action
HSBC — Reduce
90-day upgrades
2
90-day downgrades
0
Net rating momentum
+2
DateFirmActionRatingPrice target
Sep 10, 2026HSBCMaintainedReduce$165 → $175
Sep 3, 2026Piper SandlerReiteratedOverweight$225 → $245
Aug 25, 2026RBC CapitalMaintainedOutperform$240 → $260
Aug 13, 2026Wolfe ResearchUpgradePeer Perform → Outperform$300
Aug 4, 2026MizuhoMaintainedOutperform$221 → $241
Aug 3, 2026CitigroupMaintainedNeutral$200 → $215
Jul 30, 2026UBSMaintainedBuy$225 → $240
Jul 30, 2026HC Wainwright & Co.MaintainedBuy$237 → $251
Jul 30, 2026Morgan StanleyMaintainedEqual-Weight$222 → $231
Jul 30, 2026RBC CapitalMaintainedOutperform$242 → $240
Jul 30, 2026Canaccord GenuityMaintainedBuy$245 → $248
Jul 30, 2026TD CowenMaintainedBuy$215 → $225

BIIB Competitive Positioning

Biogen Inc. (BIIB) is tracked alongside these names in Drug Manufacturers - General on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

63/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Biogen Inc. (BIIB) was projected to report a modest earnings per share beat in its third‑quarter results, with analysts forecasting $2.14 versus a consensus of $2.07. Revenue was expected to hold steady at approximately $2.6 billion. The guidance was driven by expectations that lower cost of goods sold and research and development expenses would offset the impact of the upcoming lupus trial data. The company’s financial outlook remained largely unchanged, with no significant shift in strategic direction. The forecast reflects a mild positive tailwind for the company’s earnings outlook.
What did this article say?
Biogen Inc. (BIIB) reported earnings of $3.60 per share for the most recent quarter, exceeding the consensus estimate of $3.04 by 18.42%. The company’s average earnings surprise over the last two quarters was 19.72%, reinforcing its track record of beating expectations. Analysts highlighted the positive Earnings ESP and strong Zacks Rank as indicators that the earnings beat streak may persist. The consistent outperformance supports investor confidence in Biogen’s financial health and management execution. No material guidance changes or adverse events were disclosed in the report.
What did this article say?
Biogen reported that litifilimab achieved sustained efficacy over 52 weeks in the Phase 2/3 AMETHYST study for cutaneous lupus erythematosus. The proportion of patients with clear or almost clear skin rose from 27.2% at week 24 to 28.8% at week 52, while disease activity scores improved accordingly. Early responders who switched from placebo saw skin improvements within four weeks, indicating rapid onset. These results reinforce litifilimab’s potential as a first‑class therapy and may support future regulatory submissions.
What did this article say?
Biogen Inc. (NASDAQ:BIIB) disclosed 52‑week results from the Phase 2 portion of its AMETHYST Phase 2/3 study of litifilimab in patients with cutaneous lupus erythematosus. The data showed that 27.2% of participants achieved the clinical endpoint of clear or almost clear skin at week 52. The drug was generally well tolerated, with no new safety signals reported. These findings provide early evidence of efficacy but are limited by the interim nature of the data and the modest response rate.
What did this article say?
Biogen Inc. (BIIB) experienced a modest share price increase of about 0.5% on September 29 after reporting robust second‑quarter 2026 earnings that beat expectations. The company highlighted recent strategic acquisitions and positive updates to its product pipeline, reinforcing investor confidence. These developments, combined with a supportive market environment, contributed to the stock’s rise to a 52‑week high.
What did this article say?
Biogen reported its Q2 earnings during the close of the earnings season, contributing to a broader positive performance across the therapeutics sector. The company’s results helped push group revenues above analyst consensus by 8%, reflecting strong demand for rare disease treatments and precision medicine advances. Despite regulatory and pricing headwinds, Biogen’s earnings reinforced its position as a leading player in the therapeutic market. The positive outcome supports investor confidence and highlights the company’s resilience amid competitive pressures.
What did this article say?
Biogen secured Japanese approval for its at‑home LEQEMBI Pen, a subcutaneous formulation for early Alzheimer’s disease, and released Phase 3 data showing EMPAVELI improved proteinuria and stabilized kidney function in rare complement‑mediated kidney disorders. The dual announcements reinforce Biogen’s strategy to expand access to complex therapies in real‑world settings and broaden its therapeutic reach beyond neurology into nephrology. These developments are expected to strengthen the company’s growth narrative and support its Alzheimer’s‑led revenue trajectory.
What did this article say?
Biogen (BIIB) disclosed adolescent subgroup results from its Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases, providing fresh clinical evidence that may strengthen the drug’s development profile. The data suggest a favorable safety and efficacy signal in a younger cohort, potentially expanding the patient population for the therapy. While the announcement has already nudged the stock higher, it does not represent a material shift in the company’s overall outlook or valuation. Investors will monitor subsequent full data releases and regulatory feedback to gauge the long‑term impact on the drug’s commercial prospects.
What did this article say?
Biogen’s EMPAVELI received FDA label expansion to include adolescents 12 and older after a Phase 3 study showed a 75% reduction in proteinuria and stable kidney function in C3G and IC‑MPGN patients. The data, published in a peer‑reviewed journal, confirm the drug’s dual benefit of lowering proteinuria and preserving eGFR, strengthening its therapeutic profile. The approval expands the market for EMPAVELI and may drive additional sales in the nephrology segment.

Technical Analysis

Real-time indicators across multiple timeframes

86
BULLISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $16.32B combined position · 14 adding, 9 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
FMR LLC (Fidelity)▲ Buy18,217,23912.61%$3.94B2026-08-13
BlackRock, Inc.▲ Buy15,985,73611.07%$3.45B2026-08-07
Vanguard Group Inc▲ Buy17,447,09212.08%$3.07B2026-01-29
Geode Capital Management, LLC▲ Buy4,449,2953.08%$957.94M2026-08-12
Wellington Management Group LLP▲ Buy3,117,4692.16%$673.56M2026-08-14
Norges Bank▼ Sell2,580,0331.79%$557.44M2026-08-12
Morgan Stanley▲ Buy2,411,2711.67%$520.98M2026-08-13
AQR Capital Management LLC▲ Buy1,936,8591.34%$416.93M2026-08-14
JPMorgan Chase & Co▼ Sell1,823,1401.26%$394.95M2026-08-12
Invesco Ltd.▲ Buy1,803,9441.25%$389.76M2026-08-14
Susquehanna International Group, LLP▲ Buy1,647,6611.14%$355.99M2026-08-14
Northern Trust Corp▼ Sell1,429,4900.99%$308.86M2026-08-13
Goldman Sachs Group Inc▲ Buy1,270,3900.88%$274.48M2026-08-14
Bank of America Corp▼ Sell1,116,2280.77%$241.17M2026-08-14
Citadel Advisors LLC• Hold867,5560.60%$187.44M2026-09-02
Citigroup Inc▲ Buy810,8170.56%$175.19M2026-08-03
Balyasny Asset Management L.P.▼ Sell365,0900.25%$78.88M2026-08-14
Fisher Asset Management, LLC▲ Buy338,0180.23%$73.03M2026-08-04
Gotham Asset Management, LLC▼ Sell279,9000.19%$60.48M2026-08-14
Man Group plc▼ Sell196,2220.14%$42.40M2026-08-14
AllianceBernstein L.P.▲ Buy214,9750.15%$39.41M2026-08-14
Palo Alto Investors LP• Hold140,2790.10%$30.31M2026-08-18
Adage Capital Partners GP, L.L.C.▼ Sell129,5990.09%$28.00M2026-08-14
Wells Fargo & Company▲ Buy128,6640.09%$27.80M2026-08-14
Suvretta Capital Management, LLC▼ Sell132,2900.09%$23.28M2026-02-17
Q2 2026 flow:6.62M sh bought ($1.43B)957.8K sh sold ($207.06M)net +5.66M sh (+$1.22B)
Congressional Trading Activity
22 disclosed trades · ~$249.5K est. traded value · 13 buys, 9 sells
MemberChamberStateTypeAmountTradedFiled
Kevin HernHouseOK01▼ Sell$1K - $15K2026-08-182026-09-01
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-06-052026-07-02
Maria Elvira SalazarHouseFL27▼ Sell$15K - $50K2026-06-022026-07-07
Maria Elvira SalazarHouseFL27▲ Buy$1K - $15K2026-05-122026-06-08
Maria Elvira SalazarHouseFL27▲ Buy$1K - $15K2026-05-112026-06-08
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-01-302026-02-13
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-06-09
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2019-03-222019-04-17
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2018-01-082018-02-13
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2016-12-232017-01-11
Sheldon WhitehouseSenateRI▼ Sell$15K - $50K2016-12-132017-01-11
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2015-08-282015-09-24
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2015-08-102016-08-11
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2015-08-042016-08-11
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2015-07-102015-07-21
Sheldon WhitehouseSenateRI▲ Buy$15K - $50K2015-05-072015-08-12
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2015-04-072015-04-23
Susan M. CollinsSenateME▼ Sell$1K - $15K2014-07-232015-07-20
Susan M. CollinsSenateME▼ Sell$1K - $15K2014-03-272014-04-01